An FDA-Approved Drug Screen for Compounds Influencing Craniofacial Skeletal Development and Craniosynostosis. (2019)
Attributed to:
Nudc as a new molecular target to investigate the pathogenesis and treatment of skeletal ciliopathies.
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1159/000491567
PubMed Identifier: 30976283
Publication URI: http://europepmc.org/abstract/MED/30976283
Type: Journal Article/Review
Volume: 10
Parent Publication: Molecular syndromology
Issue: 1-2
ISSN: 1661-8769